Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck
This article was originally published in The Tan Sheet
Executive Summary
Bayer is expanding the scope of its eponymous aspirin brand from heart attack and stroke prevention to migraine pain
You may also be interested in...
Aspirin and migraines
Acetysalicylic acid is as effective as the Rx medication sumatriptan in relieving both migraine headaches and their symptoms, according to two studies presented in association with the Aspirin Award 2003 meeting in Fiuggi, Italy, Sept. 12. Approximately 312 patients were randomized to take two tablets of Bayer's effervescentAspirin Migraine (1,000 mg ASA), 50 mg sumatriptan, 400 mg ibuprofen or placebo. After two hours, "headaches were less severe or had disappeared altogether" in 52.2% of patients taking aspirin, Bayer states. Ibuprofen and sumatriptan both demonstrated similar effects. The second study found that two hours after administration, almost 44% of patients in the aspirin arm "were free of accompanying symptoms." Bayer was given the go-ahead to market Aspirin Migraine containing 500 mg ASA per tablet in October 2001, but has yet to market the product (1"The Tan Sheet" Nov. 5, 2001, p. 12)...
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients
Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001
Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001